Preliminary MASAI trial results indicate that AI-supported mammography has a similar rate of breast cancer detection to standard double reading while reducing the screen-reading workload.

Just under one in five women will experience at least one false–positive result during 10 years of biennial breast screening, population-based data from Norway show.

Findings on mammography included single and multiple enlarged nodes as well as adenopathy with soft tissue stranding.

Black race is a significant predictor of nonadherence to scheduled screening mammography appointments, suggests research.

“Radiology facilities could use this risk stratification model to triage individuals for mammography during periods of reduced capacity, such as that which occurred during the start of the COVID-19 pandemic,” suggests the team.

medwireNews : The US FDA has granted approval for use of the Senographe Pristina with Self-Compression digital 2-dimensional mammography system.

The median quarterly rate of prepandemic screening mammography fell by 40% between Q1 of 2017 and Q2 of 2020 (8216 vs 4951 procedures per 100,000 beneficiaries).

Women with extremely dense breasts and a high breast cancer risk have a lower risk for advanced cancer when screened by digital breast tomosynthesis than digital mammography, US study findings indicate.

The researchers identified 35,986 women aged between 50 and 74 years who had their first mammography screen at a BCSC facility during 2000–2018.

Xavier Pivot, from the Institute of Cancer Strasbourg in France, and team note that “[t]he results regarding [breast] pCR, overall response, and response based on mammography, ultrasonography, or clinical tumor evaluations supported the comparable efficacy between HD201 and referent trastuzumab.”

The models included race-specific inputs for breast cancer subtype distribution, breast density, mammography performance, age-, stage-, and subtype-specific treatment effects, and non-breast cancer mortality.

At an urban integrated health system’s safety-net hospital in San Francisco, California, 62% of the scheduled 392 mammography appointments in January 2021 were attended, which was significantly lower than the average attendance rate of 79% in the prepandemic period of September 2019–January 2020.

Women who participate in the two most recent screening mammography appointments before a breast cancer diagnosis have a significantly lower risk for death than those who do not attend or only attend one appointment, research shows.

The declines in breast cancer screening during the COVID-19 pandemic are more marked among women from minority communities and those living in rural areas, report US researchers.

The study findings are consistent with those previously reported by medwireNews [SN1]  , and Chen and team conclude that they further current knowledge by revealing “that the screening deficit was larger for breast and colorectal cancers, which require procedures (commonly, mammography and colonoscopy), compared with prostate cancer screening, which commonly involves a blood test (ie, prostate-specific antigen testing).”

Using data from the Massachusetts General Brigham healthcare system, the researchers found that 15,453 individuals underwent one of five screening tests – namely low-dose CT, Papanicolaou test, colonoscopy, prostate-specific antigen (PSA) screening, and mammography – during the first peak of the pandemic in March 2–June 2, 2020, with diagnosis of cancerous or precancerous lesions in 1985 cases.

This “[l]ack of mortality reduction in younger women is consistent with data reported in some mammography trials, and could point to undetermined biological factors,” say the researchers.